What should you pay attention to when using atezolizumab subcutaneous preparation (TECENTRIQ HYBREZA)

Before using atezolizumab subcutaneous preparation, patients and medical staff need to understand the relevant precautions to ensure the safety of the medication process. As a programmed death-ligand 1 (PD-L1) blocking antibody, the drug is used in combination with endoglycosidase to treat non-small cell lung cancer and other malignant tumors. It is injected subcutaneously and administered once every three weeks. Although it is easy to administer, it needs to be used with caution as it involves immune system modulation.

The subcutaneous formulation of atezolizumab should be avoided in patients with known hypersensitivity to any component of the formulation. Before use, patients should proactively inform their doctor of any past medical history, especially problems involving the immune system, including autoimmune diseases such as Crohn's disease, ulcerative colitis, or systemic lupus erythematosus. In addition, patients who have received an organ transplant or plan to receive a stem cell transplant need to carefully evaluate the interaction between the immune system and drugs to prevent rejection or abnormal activation of the immune system.

Some patients who have received chest radiation therapy or have neurological diseases, such as myasthenia gravis or Guillain-Barre syndrome, should also be evaluated before treatment to reduce the risk of potential adverse reactions. The drug has not yet obtained sufficient safety data in pregnant people, and animal experiment results suggest it may cause harm to the fetus. Therefore, this drug should not be used during pregnancy. If the patient becomes pregnant or suspects pregnancy during treatment, the patient should inform the doctor immediately and receive further guidance.

Women of childbearing potential should undergo a pregnancy test before treatment and use effective contraceptive measures during treatment and for at least five months after discontinuation of treatment. In addition, since it is unclear whether the drug is excreted in breast milk, it is recommended to avoid breastfeeding during treatment and for five months after the last dose to avoid exposing the baby to potential drug risks. This preparation may also affect a woman's fertility and if relevant, a doctor should be consulted before treatment.

During the course of medication, atezolizumab subcutaneous preparations should be injected by professional medical staff, and are limited to subcutaneous injections in the thigh area. Avoid injecting the solution into skin areas that are red, damaged, indurated or painful. It is recommended to inject alternately between the left and right thighs. Each injection point should be at least 2.5 cm away from the previous one. It is prohibited to use this product for intravenous injection to avoid adverse reactions or abnormal drug distribution.

Patients should inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, vitamins, and herbal supplements, to avoid possible drug interactions.

For storage, medications should be refrigerated Store between 2 and 8 degrees Celsius in the original packaging box away from light. Do not freeze or shake to maintain the stability and efficacy of the drug.

Taken together, although the subcutaneous preparation of atezolizumab provides a convenient immunotherapy method for tumor treatment, its use involves multiple clinical links, and the medication guidelines and doctor's guidance must be strictly followed to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.drugs.com/search.php?searchterm=TECENTRIQ+HYBREZA